1.Loss of Striatal Dopamine Transporter Binding in Patients and a Family Member with Familial Parkinsonism with Parkin Gene Mutation.
Joong Seok KIM ; Ki Sung KIM ; Soung Kyeong PARK ; Kwang Soo LEE
Journal of the Korean Neurological Association 2005;23(1):132-134
No abstract available.
Dopamine Plasma Membrane Transport Proteins*
;
Dopamine*
;
Humans
;
Parkinsonian Disorders*
3.Reduced Uptake on Dopamine Transporter Imaging by Methylphenidate
Joonyoung HA ; Jeongmin KO ; Jin Taek SONG ; Jin Yong HONG
Journal of the Korean Neurological Association 2019;37(2):206-208
No abstract available.
Dopamine Plasma Membrane Transport Proteins
;
Dopamine
;
Methylphenidate
;
Parkinsonian Disorders
4.Presynaptic Dopaminergic Degeneration in a Patient with Beta-Propeller Protein-Associated Neurodegeneration Documented by Dopamine Transporter Positron Emission Tomography Images: A Case Report.
Min Ki KIM ; Nan Young KIM ; Sangkyoon HONG ; Hyeo Il MA ; Yun Joong KIM
Journal of Movement Disorders 2017;10(3):161-163
No abstract available.
Dopamine Plasma Membrane Transport Proteins*
;
Dopamine*
;
Electrons*
;
Humans
;
Positron-Emission Tomography*
5.Evaluation of Striatal Dopamine Transporter Density using 123I-beta-CIT SPECT in Schizophrenic Patients Treated with Olanzapine - Pilot study.
Chul Eung KIM ; Hey Won MOON ; Won Sick CHOE ; Chang Ho KIM ; Dae Yoon CHI
Korean Journal of Nuclear Medicine 2002;36(4):224-231
No abstract available.
Dopamine Plasma Membrane Transport Proteins*
;
Dopamine*
;
Humans
;
Pilot Projects*
;
Tomography, Emission-Computed, Single-Photon*
6.Stimulants Medication of Attention-Deficit Hyperactivity Disorder.
Young Hui YANG ; Hee Jeong YOO
Journal of the Korean Academy of Child and Adolescent Psychiatry 2008;19(2):61-71
Attention-deficit hyperactivity disorder (ADHD) is characterized by inattention, hyperactivity, impulsiveness and problems in other higher cognitive processes such as executive function deficits. Currently, there are many treatment modalities, of which pharmacotherapy is the most strongly supported by scientific and clinical evidence. Stimulants, which are first choice in the pharmacological treatment of ADHD, block dopamine reuptake by binding the dopamine transporter and so increasing the concentration of dopamine in synaptic clefts. Stimulants are effective in improving core ADHD symptoms, as well as the nonspecific symptoms, such as aggressiveness and oppositional behavior. Frequently reported short-term adverse effects are decreased appetite, sleep disturbance, headache, dizziness and irritability. Although questions have been raised about the long-term side effects of stimulants, including growth suppression, cardiovascular events, and abuse potential, there is no clear evidence to support these concerns.
Appetite
;
Dizziness
;
Dopamine
;
Dopamine Plasma Membrane Transport Proteins
;
Executive Function
;
Headache
7.Association of Alcohol Dependence with the Dopamine Transporter Gene Polymorphism.
Yun Jeong CHOI ; Seung Kyu BANG ; Jung JIN ; Kyu Young TOH ; In Ho PAIK
Journal of Korean Neuropsychiatric Association 1999;38(4):826-833
OBJECTIVES: Alcoholism is known to be a heritable disease. It has been hypothesized that dopamineergic systems play an important heritable role in human behavor related to alcohol dependence, such as alcohol seeking. Therefore, genes involved in this pathway, including dopamine transporter(DAT1) which is responsible for taking released dopamine back up into presynaptic terminals and terminating dopaminergic activity, are potential candidate that may affect susceptibility to alcoholism. Analysis of a 40-base pair(bp)repeat(VNTR)in the 3'untranslated region of the DAT1 gene revealed variable number of the repeat ranging from 3 to 11 copies. Therefore, in the present study, we examined the association between alcoholism and VNTR polymorphism of DAT1. METHODS: Genomic DNA analysis with polymerase chain reaction(PCR)was used to identify the presence of a VNTR polymorphism. It was carried out within a group of 94 alcoholic patients and 113 normal controls. RESULTS: 1)There were no significant differences in allelic or genotype frequencies between the group of alcoholic patients and controls. 2)There were no significant differences in the first drinking age, onset age and latency of alcoholism according to DAT1 genotypes. 3)There was a significant difference in allelic frequencies between alcoholics with family history and those without family history. CONCLUSIONS: These results suggested that VNTR polymorphism of DAT1 is unlikely to be a factor in the genetic etiology of alcoholism, but might be related to familial transmission of alcoholism.
Age of Onset
;
Alcoholics
;
Alcoholism*
;
DNA
;
Dopamine Plasma Membrane Transport Proteins*
;
Dopamine*
;
Drinking
;
Genotype
;
Humans
;
Presynaptic Terminals
8.Functional Regulation of Dopamine D₃ Receptor through Interaction with PICK1.
Mei ZHENG ; Xiaohan ZHANG ; Chengchun MIN ; Bo Gil CHOI ; In Joon OH ; Kyeong Man KIM
Biomolecules & Therapeutics 2016;24(5):475-481
PICK1, a PDZ domain-containing protein, is known to increase the reuptake activities of dopamine transporters by increasing their expressions on the cell surface. Here, we report a direct and functional interaction between PICK1 and dopamine D₃ receptors (D₃R), which act as autoreceptors to negatively regulate dopaminergic neurons. PICK1 colocalized with both dopamine D₂ receptor (D₂R) and D₃R in clusters but exerted different functional influences on them. The cell surface expression, agonist affinity, endocytosis, and signaling of D₂R were unaffected by the coexpression of PICK1. On the other hand, the surface expression and tolerance of D₃R were inhibited by the coexpression of PICK1. These findings show that PICK1 exerts multiple effects on D₃R functions.
Autoreceptors
;
Dopamine Plasma Membrane Transport Proteins
;
Dopamine*
;
Dopaminergic Neurons
;
Endocytosis
;
Hand
9.Association between Panic Disorder and Dopamine Transporter Gene(DAT1) Polymorphism.
Seung Min BAE ; Se Won LIM ; Kang Seob OH ; Min Soo LEE
Journal of the Korean Society of Biological Psychiatry 2007;14(1):55-60
OBJECTIVES: There have been many association studies of panic disorder. However, studies about the do-paminergic function in panic disorder have been few. This study was aimed to examine the possible as-sociation of dopamine transporter gene(DAT1) polymorphism and panic disorder in Korean population. METHODS: Ninety-eight patients with panic disorder(43 male(46.9%), mean age 42.13+/-10.88 years) and one hundred and thirteen comparison subjects(67 male(40.7%), mean age 33.14+/-8.55 years) were tested for DAT1 polymorphism. Genotypes of DAT1 with variable number of tandem repeats(VNTR) were determined using polymerase chain reaction. The differences of allelic frequency and genotype frequency distribution between patient and the control group were tested with Fisher-Freeman-Halton test. RESULTS: There was association between DAT1 polymorphism and panic disorder(allele : p<0.03, genotype : p<0.05). The frequency of 10/10 homozygotes of DAT1 was significantly higher in control group(chi2=4.452, df=1, p=0.035). CONCLUSION: These results in our Korean samples suggest that DAT1 polymorphism might be associated with the vulnerability of panic disorder. Possible association of dopaminergic genes and panic disorder should be investigated with future studies using larger and different population.
Dopamine Plasma Membrane Transport Proteins*
;
Dopamine*
;
Genotype
;
Homozygote
;
Humans
;
Panic Disorder*
;
Panic*
;
Polymerase Chain Reaction
10.Radiopharmaceuticals for Neurotransmitter Imaging.
Nuclear Medicine and Molecular Imaging 2007;41(2):118-131
Neurotransmitter imaging with radiopharmaceuticals plays major role for understanding of neurological and psychiatric disorders such as Parkinson's disease and depression. Radiopharmaceuticals for neurotransmitter imaging can be divided to dopamine transporter imaging radiopharmaceuticals and serotonin trnasporter imaging radiopharmaceuticals. Many kinds of new dopamine transporter imaging radiopharmcaeuticals has a tropane ring and they showed different biological properties according to the substituted functional group on tropane ring. After the first clinical trials with [123I]beta-CIT, alkyl chain substituent introduced to tropane ring amine to decrease time for imaging acquisition and to increase selectivity. From these results, [123I]PE2I, [18F]FE-CNT, [123I]FP-CIT and [18F]FP-CIT were developed and they showed high uptake on the dopamine transporter rich regions and fast peak uptake equilibrium time within 4 hours after injection. [11C]McN 5652 was developed for serotonin trnasporter imaging but this compound showed slow kinetics and high background radioactivity. To overcome these problems, new diarylsulfide backbone derivatives such as ADAM, ODAM, AFM, and DASB were developed. In these candidates, [11C]AFM and [11C]DASB showed high binding affinity to serotonin transporter and fast in vivo kinetics. This paper gives an overview of current status on dopamine and serotonin transporter imaging radiopharmaceuitcals and the development of new lead compounds as potential radiopharmaceuticals by medicinal chemistry.
Chemistry, Pharmaceutical
;
Depression
;
Dopamine
;
Dopamine Plasma Membrane Transport Proteins
;
Kinetics
;
Neurotransmitter Agents*
;
Parkinson Disease
;
Radioactivity
;
Radiopharmaceuticals*
;
Serotonin
;
Serotonin Plasma Membrane Transport Proteins
;
Tomography, Emission-Computed, Single-Photon